Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  SenzaGen AB    SENZA   SE0010219626

SENZAGEN AB

(SENZA)
  Report
End-of-day quote. End-of-day quote NASDAQ OMX STOCKHOLM - 09/25
22 SEK   +0.92%
09/16SENZAGEN : Global medical device company places SEK 0.6 million order
AQ
09/11SENZAGEN : receives order for GARD™skin and GARD™potency from a major US chemical company
AQ
SummaryChartsNewsCompanyFinancials 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

SenzaGen: Global medical device company places SEK 0.6 million order

share with twitter share with LinkedIn share with facebook
09/16/2020 | 04:06am EDT

A global medical device company has decided to continue using SenzaGen’s most recently launched test, GARD®skin Medical Device, for risk assessment of their materials to prevent skin allergies. The order is valued at approximately SEK 0.6 million, and the tests will be performed in accordance with the OECD Principles of Good Laboratory Practice (GLP) at SenzaGen’s laboratory in Lund.

The medical device company placed the order after evaluating the GARD test method on a small scale earlier this year. The company operates globally based out of Europe and engages in innovative product development in-house with an aim to replace animal testing with alternative methods in the material risk assessment process to the greatest degree possible.

“We are very pleased with this key customer’s continued trust in both SenzaGen and our tests. Our test method gives the customer rapid and reliable answers to whether substances in their products can cause allergies, even for substances that are traditionally more difficult to test. The order shows that we meet the needs of the medical device industry, one of the industries we prioritize in our marketing and sales activities," says SenzaGen CEO Axel Sjöblad.

Launched in fall 2019, the GARD®skin Medical Device test provides a highly accurate and ethical alternative to skin sensitization testing of materials in medical devices. An update process is currently underway for the global medical device ISO standard, which advocates the inclusion of alternative risk assessment methods to replace animal testing in biological evaluation for medical device filings. SenzaGen’s goal is for GARD®skin Medical Device to be included in the new ISO standard.

© Modular Finance, source Nordic Press Releases

share with twitter share with LinkedIn share with facebook
All news about SENZAGEN AB
09/16SENZAGEN : Global medical device company places SEK 0.6 million order
AQ
09/11SENZAGEN : receives order for GARD™skin and GARD™potency from a majo..
AQ
More news
Financials
Sales 2019 4,92 M 0,54 M 0,54 M
Net income 2019 -50,2 M -5,50 M -5,50 M
Net cash 2019 120 M 13,2 M 13,2 M
P/E ratio 2019 -6,00x
Yield 2019 -
Capitalization 470 M 51,4 M 51,5 M
EV / Sales 2018 47,0x
EV / Sales 2019 56,6x
Nbr of Employees 17
Free-Float 84,2%
Chart SENZAGEN AB
Duration : Period :
SenzaGen AB Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Axel Sjöblad Chief Executive Officer
Karl Arne Krister Borrebaeck Chairman
Marianne Olsson Chief Financial Officer
Gunilla Grundström Chief Scientific Officer
Ann Ulrika Gidner Director
Sector and Competitors
1st jan.Capitalization (M$)
SENZAGEN AB17.90%51
EXACT SCIENCES CORPORATION1.98%14 671
GUARDANT HEALTH, INC.43.08%11 116
BGI GENOMICS CO., LTD.112.56%8 477
ADAPTIVE BIOTECHNOLOGIES CORPORATION61.40%6 557
INVITAE CORPORATION176.94%5 887